Cantor Fitzgerald Reduces Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE - Free Report) - Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Pfizer in a note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will post earnings per share of $3.09 for the year, down from their previous forecast of $3.10. Cantor Fitzgerald has a "Neutral" rating and a $24.00 price target on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer's FY2026 earnings at $3.09 EPS.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period last year, the business posted $0.82 earnings per share.

Other equities analysts have also issued research reports about the stock. UBS Group upped their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Bank of America upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets lowered their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Finally, HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $28.55.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.13 during trading on Thursday, hitting $25.66. 17,420,998 shares of the stock were exchanged, compared to its average volume of 41,747,302. The stock's fifty day moving average is $23.86 and its 200 day moving average is $24.81. The stock has a market cap of $145.86 billion, a PE ratio of 18.58, a P/E/G ratio of 0.93 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.70%. Pfizer's dividend payout ratio is currently 124.64%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently bought and sold shares of the stock. Clarity Asset Management Inc. purchased a new position in Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Finally, Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.